Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 19;13(1):34.
doi: 10.1186/s40478-025-01939-8.

Density and entropy of immune cells within the tumor microenvironment of primary tumors and matched brain metastases

Affiliations

Density and entropy of immune cells within the tumor microenvironment of primary tumors and matched brain metastases

Markus Kleinberger et al. Acta Neuropathol Commun. .

Abstract

Background: Tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) have increasingly been reported to impact the brain metastatic process of solid tumors. However, data on intra-individual differences between primary tumor and brain metastasis (BM), as well as their correlation with clinical outcome parameters, is scarce.

Methods: We retrospectively identified patients who received resection of the primary tumor and BM between 01/1990 and 10/2022. Density quantification of TAMs (CD68+, CD163+) and TILs (CD3+, CD8+, CD45RO+, FOXP3+) was performed by immunohistochemical staining of matched tumor tissue samples. Images were processed with QuPath software and heterogeneity of generated heatmaps was measured by Shannon Entropy. Time-to-BM (TTBM) was defined as the time from diagnosis of the primary tumor until the first diagnosis of BM.

Results: In total, 104 patients (46.2% female; median age 57.3 years at BM diagnosis) were included: 78/104 (75%) non-small cell lung cancer, 18/104 (17%) breast cancer, 8/104 (8%) renal cell carcinomas. Densities of CD3+ (p < 0.001) and CD8+-TILs (p < 0.001) were higher in primary tumor samples, while CD68+ (p = 0.035) and CD163+-TAM densities (p < 0.001) were higher in the matched BM. Higher CD3+, CD8+-TILs and CD163+-TAMs densities in primary tumors were associated with shorter TTBM (p = 0.005, p = 0.015 and p = 0.006, respectively). Higher entropies of CD3+ (p < 0.001) and FOXP3+ (p = 0.011) TILs were observed in primary tumors compared to BM. Longer TTBM was associated with higher entropy of FOXP3+ TILs (p = 0.024) and lower entropy in CD163+ TAMs (p = 0.039). No significant associations of immune cell densities or entropies with OS after BM diagnosis were found.

Discussion: By utilizing a unique cohort of matched primary tumor and BM tissue samples, we could demonstrate higher TIL densities in primary tumors and higher TAM densities in BM, respectively. Higher cell densities of CD3+, CD8+-TILs and CD163+-TAMs in primary tumors were associated with shorter TTBM, while a larger difference between CD3+ and CD8+ densities between primary tumor and BM was associated with longer TTBM. These findings highlight the potential of targeting TAMs as a therapeutic strategy to mitigate the development of brain metastases.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This study was approved by the Ethics Committees of the Medical University of Vienna (approval no. 1692/2022, 1895/2022). Consent for publication: Not applicable. Competing interests: M.J.M. received research funding from Bristol-Myers Squibb and travel support from Pierre Fabre. A.S.B. received research support from Daiichi Sankyo, Roche, and honoraria for lectures, consultation or advisory board participation from Roche, Bristol-Meyers Squibb, Merck, Daiichi Sankyo as well as travel support from Roche, Amgen and AbbVie. Z.S. is a former employee of Boehringer Ingelheim and Turbine AI. M.P. received honoraria for lectures, consultation, or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen. J.N.K declares consulting services for Bioptimus, France; Owkin, France; DoMore Diagnostics, Norway; Panakeia, UK; AstraZeneca, UK; Scailyte, Switzerland; Mindpeak, Germany; and MultiplexDx, Slovakia. Furthermore he holds shares in StratifAI GmbH, Germany, has received a research grant by GSK, and has received honoraria by AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Janssen, MSD, BMS, Roche, Pfizer and Fresenius.

Figures

Fig. 1
Fig. 1
Workflow of data acquisition. (1) FFPE tumor tissue samples were cut and stained with IHC for TIL and TAM marker. (2) After scanning digitalized slides were further analyzed with QuPath. Tissue was detected automatically, and false positive contamination was removed manually. (3) Positive cell detection for tissue annotations. (4) Pixel classification for regions of interest (tumor, necrosis, gap). Tumor maps generated and exported by automatic script. (5) Generating density maps for positive cells. (6) Entropy indices were calculated by using density and tumor map. Shannon entropy and cell densities [cells/mm2] were correlated with patient characteristics and outcome parameters. Graphical abstract was designed with Biorender
Fig. 2
Fig. 2
Immunohistochemical staining of TILs and TAMs in primary tumor and matched brain metastasis
Fig. 3
Fig. 3
Differences in immune cell densities between primary tumor and matched brain metastasis (BM). Boxplots indicating significantly higher cell densities [cells/mm2] of (a) CD3 + TILs (total TCR + lymphocytes; p < 0.001) and (b) CD8 + cytotoxic TILs (CD8 + T lymphocytes; p < 0.001) in primary tumors compared to brain metastasis (BM). Significantly higher cell densities were found in BM compared to primary tumors regarding (d) CD68 + TAMs (pan-macrophages; p = 0.035) and (e) CD163 + M2-like TAMs (alternatively activated macrophages; p < 0.001). No significant differences were found in (c) CD45RO + memory T cells (p = 0.3) and (f) FOXP3 + regulatory T cells (Tregs, p = 0.377). ***p < 0.001; **p < 0.01; *p < 0.05; ns . non significant
Fig. 4
Fig. 4
Differences in immune cell entropies between primary tumor and matched brain metastasis (BM). Boxplots indicating significantly higher entropy values of (a) CD3 + TILs (total TCR + lymphocytes; p < 0.001) and (f) FOXP3 + regulatory T cells (Tregs) in primary tumors compared to brain metastasis (BM; p = 0.011). No significant differences were found in (b) CD8 + cytotoxic TILs (CD8 + T lymphocytes), (c) CD45RO + memory T cells, (d) CD68 + TAMs (pan-macrophages) or (e) CD163 + M2-like TAMs (alternatively activated macrophages) (all p > 0.05). ***p < 0.001; **p < 0.01; *p < 0.05; ns . non significant

Similar articles

References

    1. Jin MZ, Jin WL (2020) The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther 5:166 - PMC - PubMed
    1. Bader JE, Voss K, Rathmell JC (2020) Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. Mol Cell 78:1019–1033 - PMC - PubMed
    1. Bejarano L, Jordāo MJC, Joyce JA (2021) Therapeutic targeting of the tumor microenvironment. Cancer Discov 11:933–959 - PubMed
    1. Wischnewski V, Maas RR, Aruffo PG et al (2023) Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation. Nat Cancer 4:908–924 - PMC - PubMed
    1. Yang B, Li X, Zhang W et al (2022) Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis. Cell Rep Med 3:100856 - PMC - PubMed

Publication types

MeSH terms